Innovent Biologics, Inc. (1801.HK)
Develops antibody drugs treating cancer, eye disease, and autoimmune conditions across China and globally.
88.90-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-4.4%
The outlook
Innovent Biologics trades at 88.9 HK, sitting above both its 50- and 200-day moving averages and roughly midway in its 52-week range. Analysts strongly back the stock with an average target implying roughly 32% upside from current levels, though the trailing P/E of 161.6 reflects a premium valuation. The overall sentiment leans notably bullish among coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 25 analysts
Price trendAbove its 50- & 200-day averages
52-week range49% of the way from its 52-week low to high
Price targetAvg target +32% vs current price
Analyst price target
~12-month · 25 analysts117.50average target+32.2% vs now
Now 88.90
Low 83.39High 139.99
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$154.77B
52-wk high
109.10
52-wk low
69.55
50-day avg
82.34
200-day avg
85.24
Trailing P/E
161.6